CoChat

Letter to the Editor:R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity

Open access
Hashimoto, K. · 2016 · Psychological Medicine
Cited by 54

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

I read with great interest the recent article by Kishimoto et al. (2016) about meta-analysis of the antidepressant effects of the N-methyl-D-aspartate receptor (NMDA-R) antagonist ketamine (racemate) and non-ketamine NMDA-R antagonists (traxoprodil, lanicemine, rapastinel) in patients with major depressive disorder (MDD) and bipolar disorder. The authors examined the time trajectory of efficacy of ketamine and non-ketamine NMDA-R antagonists. The greater reduction in depressive symptoms by ketamine infusion started as early as within 40–60 min, peaking on day 1, and lasting until days 5–8, with maintenance of superior remission and response status until days 3–5 and 7, respectively. Effect sizes of ketamine ranged from medium to high (−0.38 to −1.00). In contrast to ketamine, single infusion of non-ketamine NMDA-R antagonists was only significantly superior to placebo at one assessment time point (days 5–8) with a small to medium effect size (−0.37). Together, it is likely that non-ketamine NMDA-R antagonists have smaller effect sizes than ketamine, although the reason underlying this difference remains unclear. Ketamine (or RS-ketamine) (Ki = 0.53 μM for NMDAR) is a racemic mixture containing equal parts of R-ketamine and S-ketamine (esketamine). Esketamine shows an approximately 3to 4-fold greater anaesthetic potency and greater undesirable psychotomimetic side effects, compared with R-ketamine (Domino, 2010). This is related to the fact that esketamine (Ki = 0.30 μM) has an approximately 4-fold greater affinity for NMDA-R relative to R-ketamine (Ki = 1.4 μM) (Fig. 1) (Ebert et al. 1997). We reported that R-ketamine showed greater potency and longer-lasting antidepressant effects than esketamine in animal models of depression (Zhang et al. 2014; Yang et al. 2015). It is therefore unlikely that NMDA-R has a major role in the long-lasting antidepressant effects of R-ketamine, although antagonism at this receptor may promote its rapid antidepressant action (Hashimoto, 2014; Zhang et al. 2014; Yang et al. 2015). Unlike esketamine, R-ketamine does not induce psychotomimetic side effects and abuse potential in rodents (Yang & Hashimoto, 2014; Yang et al. 2015). Furthermore, a single dose of esketamine, but not R-ketamine, resulted in loss of parvalbumin (PV)-immunoreactivity in the prefrontal cortex (Yang et al. 2015). A recent study using [C]raclopride and positron emission tomography showed a marked reduction of dopamine D2/3 receptor binding in the conscious monkey striatum after single infusion of esketamine, but not R-ketamine (Hashimoto et al. 2016). Singh et al. (2015) reported that psychotomimetic side effects were the highest at 40 min after single infusion of esketamine although a rapid-onset antidepressant effect was shown in treatment-resistant patients with MDD. Considering the role of dopamine release in psychosis, it is likely that marked release of dopamine from presynaptic terminals in the striatum could be associated with psychotomimetic side effects in humans after a single infusion of ketamine or esketamine. The authors also pointed out that the transient efficacy lasting 1 week post-infusion of ketamine has stimulated multi-infusion studies (Kishimoto et al. 2016). Studies using repeated ketamine (or esketamine) infusions resulted in the marked psychotomimetic side effects after an each infusion although antidepressant effects were shown (Aan het Rot et al. 2010; Murrough et al. 2013; Singh et al. 2015). Interestingly, there was no difference in dissociative, psychotomimetic, or high feeling between responders and non-responders (Murrough et al. 2013), suggesting that ketamine’s antidepressant effects are not associated with its psychotomimetic effects. Recently, we reported that repeated, intermittent administration of esketamine, but not R-ketamine, caused loss of PV-immunoreactivity in the prefrontal cortex of mouse brain (Yang et al. 2016). Since loss of PV-immunoreactivity in the prefrontal cortex may be associated with psychosis and γ-oscillation deficits in schizophrenia (Gonzalez-Burgos et al. 2015), it is possible that repeated administration of esketamine or ketamine may have long-lasting detrimental side effects in the prefrontal cortex of humans. In conclusion, the use of R-ketamine in the treatment of depression would provide a new therapeutic approach by reducing the detrimental side effects of ketamine.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1017/s0033291716000969

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 54

Metadata

Authors
Hashimoto, K.
Venue
Psychological Medicine
Published
2016-06-10
Volume
46
Issue
11
Pages
2449-2451
ISSN
  • 0033-2917 (ISSN-L)
  • 1469-8978
OpenAlex
W2418304136
Cited by
54
References
7
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Letter to the Editor:R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity. https://app.cochat.ai/papers/10.1017/s0033291716000969
The paper
Hashimoto, K. (2016). Letter to the Editor:R-ketamine: a rapid-onset and sustained antidepressant without risk of brain toxicity. Psychological Medicine. https://doi.org/10.1017/s0033291716000969

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.